203 related articles for article (PubMed ID: 31325724)
1. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
[TBL] [Abstract][Full Text] [Related]
2. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
Terasawa F; Kani S; Hongo M; Okumura N
Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and biophysical conditions for blood clot lysis.
Sabovic M; Blinc A
Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
[TBL] [Abstract][Full Text] [Related]
4. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot.
Gulla KC; Gupta K; Krarup A; Gal P; Schwaeble WJ; Sim RB; O'Connor CD; Hajela K
Immunology; 2010 Apr; 129(4):482-95. PubMed ID: 20002787
[TBL] [Abstract][Full Text] [Related]
5. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy.
Sakharov DV; Nagelkerke JF; Rijken DC
J Biol Chem; 1996 Jan; 271(4):2133-8. PubMed ID: 8567670
[TBL] [Abstract][Full Text] [Related]
6. Protein C and fibrinolysis: a link between coagulation and fibrinolysis.
de Fouw NJ; Haverkate F; Bertina RM
Adv Exp Med Biol; 1990; 281():235-43. PubMed ID: 2102614
[TBL] [Abstract][Full Text] [Related]
7. Co-ordinated spatial propagation of blood plasma clotting and fibrinolytic fronts.
Zhalyalov AS; Panteleev MA; Gracheva MA; Ataullakhanov FI; Shibeko AM
PLoS One; 2017; 12(7):e0180668. PubMed ID: 28686711
[TBL] [Abstract][Full Text] [Related]
8. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
9. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
10. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.
von dem Borne PA; Meijers JC; Bouma BN
Blood; 1995 Oct; 86(8):3035-42. PubMed ID: 7579397
[TBL] [Abstract][Full Text] [Related]
11. Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro.
Zamarron C; Lijnen HR; Collen D
Thromb Res; 1984 Aug; 35(3):335-45. PubMed ID: 6431630
[TBL] [Abstract][Full Text] [Related]
12. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
Farrehi PM; Zhu Y; Fay WP
J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
[TBL] [Abstract][Full Text] [Related]
13. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
14. Effect of hirudin on tissue plasminogen activator induced clot lysis.
Electricwala A; Atkinson T
Blood Coagul Fibrinolysis; 1990 Aug; 1(3):267-71. PubMed ID: 2129413
[TBL] [Abstract][Full Text] [Related]
15. Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level.
Wun TC; Capuano A
Blood; 1987 May; 69(5):1354-62. PubMed ID: 3105619
[TBL] [Abstract][Full Text] [Related]
16. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
17. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
18. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
Hauptmann J; Glusa E
Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
[TBL] [Abstract][Full Text] [Related]
20. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma.
Carr ME; Dent RM; Carr SL
J Lab Clin Med; 1996 Jul; 128(1):83-8. PubMed ID: 8759939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
